MedPath

Moderna mpox mRNA vaccine shows early promise in monkey study - Clinical Trials Arena

Moderna's mRNA vaccine for mpox shows higher efficacy than Bavarian Nordic's Jynneos in preventing severe disease and reducing virus levels in monkeys, according to a study published in Cell. The vaccine also reduced viral replication and lesion formation, potentially limiting spread. Moderna is currently conducting a Phase I/II trial in the UK, with data expected in mid-2025.


Reference News

Moderna mpox mRNA vaccine shows early promise in monkey study

Moderna's mRNA vaccine for mpox shows higher efficacy than Bavarian Nordics' Jynneos in preventing severe disease and reducing virus levels in monkeys, according to a study published in Cell. The vaccine also reduces viral replication and lesion formation, potentially limiting spread. Moderna is currently conducting a Phase I/II trial in the UK, with results expected in mid-2025.

Moderna mpox mRNA vaccine shows early promise in monkey study - Clinical Trials Arena

Moderna's mRNA vaccine for mpox shows higher efficacy than Bavarian Nordic's Jynneos in preventing severe disease and reducing virus levels in monkeys, according to a study published in Cell. The vaccine also reduced viral replication and lesion formation, potentially limiting spread. Moderna is currently conducting a Phase I/II trial in the UK, with data expected in mid-2025.

Moderna mpox vaccine offers better protection against new strain | Drug Discovery News

Mpox, caused by monkeypox virus (MPXV), re-emerged in 2024 with clade I strains spreading faster and being deadlier. A new study led by researchers from the United States Army Medical Research Institute of Infectious Diseases, the National Institutes of Health, Boston University, and Moderna, published in *Cell*, demonstrated that mRNA-based vaccines, like mRNA-1769, could be more effective than the modified vaccinia Ankara (MVA) vaccine in protecting against severe mpox disease in macaques. The mRNA-1769 vaccine, targeting four MPXV antigens, showed tenfold fewer lesions and reduced viral load compared to MVA, highlighting the potential of mRNA technology to combat MPXV-like viruses.

© Copyright 2025. All Rights Reserved by MedPath